

Peer review activities, research grants and publications for Anthony E.T. Yeo

Reviewer activities

Have reviewed for

- The Journal of Infectious Diseases.
- Clinical infectious Diseases.
- American Journal of Gastroenterology.
- Experimental Parasitology.
- Pancreatology.
- Journal of Dental and Oral Health.
- BMJ Open

- *Guest editor for a special edition of “Anti-cancer agents in Medicinal Chemistry” 2014 volume 14, volume 2.*

Grants

- USA. Funding source: NIH 5P20RR016466-05; position: Principal investigator, 2005.

Title of project: Hepatocellular Carcinoma & End-Stage Liver Disease in Native Alaskans with HBV.

Amount for 2005: \$228,653 US dollars.

- USA. Funding source: NIH 5P20RR016466-06; position: Principal investigator, 2006.

Title of the project: Epidemiology of Hepatocellular Carcinoma & End-Stage Liver Disease in Native Alaskans with HBV.

Amount for 2006: \$200,769 US dollars.

- Australia. Funding source: NHMRC APP1022007; position: Co-principal investigator 2012-2015.

Title of the project: Improving maternal and infant outcomes: A multicentre randomised controlled trial of midwifery and dental intervention.

Amount awarded: \$443,510 Australian dollars.

Publications

1. Yeo AET, Rieckmann KH. Unexpected response to treatment of falciparum malaria illness. Medical Journal of Australia 1992; 156:367. PMID: 1588888

2. Yeo AET, Edstein MD, Shanks GD. Proguanil combined with dapsone chemoprophylaxis for malaria. Medical Journal of Australia 1992; 156:883. PMID: 1603019

3. Yeo AET, Rieckmann KH. The activity *in vitro* of cycloguanil and pyrimethamine in combination against *Plasmodium falciparum*. Transactions of the Royal Society of Tropical Medicine and Hygiene 1992; 86:234. PMID: 1412640

4. Frances SP, Yeo AET, Brooke EW, Sweeney AW. Clothing impregnations to dibutylphthalate and permethrin as protectants against a chigger mite, *Eutrombicula hirsti*. Journal of Medical Entomology 1992; 29:907-910. PMID: 1460626

5. Yeo AET, Rieckmann KH. A bioassay for mefloquine. *Journal of Parasitology* 1992; 78:1096-1097. PMID: 1491307
6. Rieckmann KH, Yeo AET, Davis DR, Hutton DC, Wheatley PF, Simpson R. Recent military experience with malaria chemoprophylaxis. *Medical Journal of Australia* 1993; 158:446-449. PMID: 8469191
7. Yeo AET, Rieckmann KH. The *in vitro* antimalarial activity of chloramphenicol against *Plasmodium falciparum*. *Acta Tropica* 1994; 56:51-54. PMID: 8203295
8. Yeo AET, Rieckmann KH. Prolonged exposure of *Plasmodium falciparum* to ciprofloxacin increases antimalarial activity. *Journal of Parasitology* 1994; 80:158-160. PMID: 8308653
9. Yeo AET, Rieckmann KH. The activity of PS-15 in combination with sulfamethoxazole. *Tropical Medicine and Parasitology* 1994; 45:136-138. PMID: 7939165
10. Yeo AET, Edstein MD, Shanks GD, Rieckmann KH. A statistical analysis of the antimalarial activity of proguanil and cycloguanil in human volunteers. *Annals of Tropical Medicine and Parasitology* 1994; 88:587-594. PMID: 7893172
11. Yeo AET, Rieckmann KH. Increased antimalarial activity of azithromycin during prolonged exposure of *Plasmodium falciparum in vitro*. *International Journal for Parasitology* 1995; 25:531-532. PMID: 7635629
12. Edstein MD, Yeo AET, Kyle DE, Looareesuwan S, Wilairatana P, Rieckmann KH. Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone *in vitro*. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1996; 90:418-421. PMID: 8882194
13. Rieckmann KH, Yeo AET, Edstein MD. Activity of PS-15 and its metabolite, WR99210, against *Plasmodium falciparum* in an *in vitro/in vivo* model. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1996; 90:568-571. PMID: 8944276
14. Yeo AET, Seymour KK, Rieckmann KH, Christopherson RI. Effects of folic and folinic acid on the activities of cycloguanil and WR99210 against *Plasmodium falciparum in erythrocytic culture*. *Annals of Tropical Medicine and Parasitology* 1997; 91:17-23. PMID: 9093425
15. Yeo AET, Rieckmann KH. The activity of triple combinations of antifolate biguanides, with and without of folinic acid, against *Plasmodium falciparum*. *Annals of Tropical Medicine and Parasitology* 1997; 91:247-252. PMID: 9229018
16. Yeo AET, Seymour KK, Rieckmann KH, Christopherson RI. Effects of dual combinations of antifolates and atovaquone or dapsone on nucleotide levels in *Plasmodium falciparum*. *Biochemical Pharmacology* 1997; 53:943-950. PMID: 9174107

17. Edstein MD, Yeo AET, Shanks GD, Rieckmann KH. *Ex vivo* antimalarial activity of proguanil combined with dapsone against cycloguanil resistant *Plasmodium falciparum* isolates. *Acta Tropica* 1997; 66:127-135. PMID: 9210963
18. Yeo AET, Edstein MD, Shanks GD, Rieckmann KH. Potentiation of the antimalarial activity of atovaquone by doxycycline against *Plasmodium falciparum* *in vitro*. *Parasitology Research* 1997; 83:489-491. PMID: 9197398
19. Yeo AET, Edstein MD, Rieckmann KH. Antimalaria activity of the triple combination of atovaquone, proguanil and dapsone. *Acta Tropica* 1997; 67:207-214. PMID: 9241385
20. Yeo AET. Direct comparison of antimalarial activity among PS-15 combination therapies by bioassay of serum samples from treated *Saimiri sciureus*. *Journal of Parasitology* 1997; 83:515-518. PMID: 9194836
21. Seymour KK, Yeo AET, Rieckmann KH, Christopherson RI. dCTP levels are maintained in *Plasmodium falciparum* subjected to pyrimidine deficiency or excess. *Annals of Tropical Medicine and Parasitology* 1997; 91:603-609. PMID: 9425362
22. Yeo AET, Christopherson RI. Comparative effects of cycloguanil and WR99210 in malaria-infected erythrocytes and human leukaemia cells. *Annals of Tropical Medicine and Parasitology* 1998; 92:331-333. PMID: 9713549
23. Yeo AET, Rieckmann KH, Christopherson RI. Indirect inhibition by antibiotics of nucleotide and deoxynucleotide biosynthesis in *Plasmodium falciparum*. *South East Asian Journal of Tropical Medicine and Public Health* 1998; 29:24-26. PMID: 9740262
24. Christopherson RI, Seymour KK, Yeo AET. Pyrimidine antagonists and antifolates as antimalarial drugs. *Advances in Biological and Experimental Medicine* 1998; 431:705-709. PMID: 9598156
25. Matsumoto A, Yeo AET, Shih WK, Tanaka E, Kiyosawa K, Alter HJ. Transfusion associated TT virus infection and its relationship to liver disease. *Hepatology* 1999; 30:283-288. PMID: 10385668
26. Yeo AET, Matsumoto A, Shih WK, Alter HJ, Goedert JJ. Prevalence of Hepatitis G virus in hemophilia patients and their steady female sexual partners. *Sexually Transmitted Diseases* 2000; 27:179-182. PMID: 10726654
27. Yeo AET, Matsumoto A, Hisada M, Shih WK, Alter HJ, Goedert JJ. The effect of hepatitis G infection on progression of HIV infection in patients with hemophilia. *Annals of Internal Medicine* 2000; 132:959-963. PMID: 10858179
28. Tanaka Y, Primi D, Wang RYH, Umemura T, Yeo AET, Mizokami M, Alter HJ, Shih JWK. Genomic and molecular evolutionary analysis of a newly identified infectious agent (SEN virus) and its relationship to the TT virus family. *Journal of Infectious Diseases*, 2001; 183:359-367.

PMID: 1113336

29. Umemura T, Yeo, AET, Sottini A, Moratto D, Tanaka Y, Wang RH, Shih JWK, Donahue P, Primi D, Alter HJ. SEN Virus Infection and Its Relationship to Transfusion-Associated Hepatitis. *Hepatology* 2001; 33:1303-1311. PMID: 11343260

30. Yeo AET, Ghany M, Conry-Cantilena C, Melpolder JC, Kleiner DE, Shih JWK, Hoofnagle JH, Alter HJ. Stability of HCV RNA levels and its lack of correlation with disease severity in asymptomatic chronic Hepatitis C virus carriers. *Journal of Viral Hepatitis* 2001; 8:256-263. PMID: 11454176

31. Umemura T, Alter HJ, Tanaka E, Yeo AET, Shih JWK, Orii K, Matsumoto A, Yoshizawa K, Kiyosawa K. Association between SEN virus infection and hepatitis C in Japan. *Journal of Infectious Diseases* 2001; 184:1246-1251. PMID: 11679912

32. Umemura T, Alter HJ, Tanaka E, Orii K, Yeo AET, Shih JWK, Matsumoto A, Yoshizawa K, Kiyosawa K. SEN Virus: Response to Interferon-Alfa and Influence on the Severity and Treatment Response of Coexistent Hepatitis C. *Hepatology* 2002; 35:953-959. PMID: 11915044

33. Tanaka Y, Hanada K, Mizokami M, Yeo AET, Shih JWK, Gojobori T, Alter HJ. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. *Proceedings of the National Academy of Sciences* 2002; 99:15584-15589. PMID: 12438687

34. Thielking DM, Destefano MS, Cynamon MH, Yeo AE. Enhanced *In Vitro* Activity of Dihydrofolate Reductase and Dihydropteroase Synthase Inhibitors in Combination against *Nocardia spp.* *Antimicrob Agents Chemother* 2003; 47:1174. PMID: 12604567

35. Tanaka Y, Furuta T, Suzuki S, Orito E, Yeo AE, Hirashima N, Sugauchi F, Ueda R, Mizokami M. Impact of interleukin-1 beta genetic polymorphism on development of hepatitis C virus-related hepatocellular carcinoma in Japan. *The Journal of Infectious Diseases* 2003; 187: 1822-1825. PMID: 12751042

36. Pfeiffer RM, Tanaka Y, Yeo AE, Umemura T, Seal KH, Shih JW, Alter HJ, Edlin BR, O'Brien TR. Prevalence of SEN Viruses among Injection Drug Users in the San Francisco Bay Area. *The Journal of Infectious Diseases* 2003; 188:13-18. PMID: 12825166

37. Yeo AET, Tanaka Y, Furuta T. Interleukin 1 β polymorphism and hepatitis C virus related hepatocellular carcinoma. *Hepatology* 2003; 38:267-268. PMID: 12830011

38. Cynamon MH, Elliott SA, DeStefano MS, Yeo AET. Activity of Clarithromycin Alone and in Combination in a Murine Model of *M. kansasii* Infection. *The Journal of Antimicrobial Chemotherapy* 2003; 52:306-307. PMID: 12837729

39. Umemura T, Tanaka E, Lee WM, Manns MP, Hatzakis A, Brown KE, Young NS, Wang

- RWH, Yeo AET, Shih JWK, Orii K, Kiyosawa K Alter HJ. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis associated aplastic anemia or acute and chronic non-A to E hepatitis. *The Journal of Infectious Diseases* 2003; 188:1545-1552. PMID: 14624381
40. Alvarez-Freites E, Yeo AE, DeStefano MS, Cynamon MH. *In vitro* Susceptibility of *Nocardia* Species to Cethromycin, Clarithromycin and Amikacin. *The European Journal of Clinical Microbiology and Infectious Diseases* 2004; 23:69-70. PMID: 14666401
41. Cynamon MH, Alvarez-Freites E, Yeo AE. BB-3497, a peptide deformylase inhibitor, is active against *Mycobacterium tuberculosis*. *Journal of Antimicrobial Chemotherapy* 2004; 53: 403-405. PMID: 14688038
42. Tanaka Y, Pfeiffer R, Yeo AE, Mizokami M, Edlin BR, Castle P, O'Brien TR, Alter HJ, Shih JW. PCR-probe capture hybridization assay and statistical model for SEN virus prevalence estimation. *Journal of Medical Virology* 2004; 73:123-130. PMID: 15042659
43. Cynamon MH, Sklaney M, Yeo AE. The activity of grepafloxacin in two murine models of *Mycobacterium avium* infection. *Journal of Infection and Chemotherapy* 2004; 10:185-188. PMID: 15290460
44. Tanaka Y, Yeo AE, Orito E, Ito K, Hirashima N, Ide T, Sata M, Mizokami M. Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection. *Journal of Gastroenterology* 2004; 39:769-775. PMID: 15338371
45. Morishima C, Paschal DM, Wang CC, Yoshihara CS, Wood BL, Yeo AE, Emerson SS, Shuhart MC, Gretch DR. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. *Hepatology*. 2006; 43:573-580. PMID: 16496327
46. Bartman MT, Kaidarova Z, Hirschhorn D, Sacher RA, Fridey J, Garratty G, Gible J, Smith JW, Newman B, Yeo AE, Murphy EL. Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection. *Blood*. 2008; 112:3995-4002. PMID: 18755983
47. Yuan Q, Ou SH, Chen CR, Ge SX, Pei B, Chen QR, Yan Q, Lin YC, Ni HY, Huang CH, Yeo AE, Shih JW, Zhang J, Xia NS. Molecular Characteristics of Occult Hepatitis B Virus from Blood Donors in the southeast China. *J Clin Microbiol* 2010; 48:357-362. PMID: 19940057
48. Li A, Yuan Q, Huang Z, Fan J, Guo R, Lou B, Zheng Q, Ge S, Chen Y, Su Z, Yeo AE, Chen Y, Zhang J, Xia N. A novel double-antigen sandwich immunoassay for human hepatitis B core antibody. *Clin Vaccine Immunol*. 2010; 17:464-469. PMID: 20107008
49. Chen Y, Xu F, Gui X, Yang K, Wu X, Zheng Q, Ge S, Yuan Q, Yeo AE, Zhang J, Guan Y, Chen H, Xia N. A rapid test for the detection of influenza A virus including pandemic influenza A/H1N1 2009. *J Virol Methods* 2010; 167:100-102. PMID: 20144656
50. Zheng ZZ, Miao J, Zhao M, Tang M, Yeo AE, Yu H, Zhang J, Xia NS. The role of Heat

Shock Protein 90 (HSP 90) in Hepatitis E Virus (HEV) Capsid Trafficking. *J Gen Virol.* 2010; 91:1728-1736. PMID: 20219895

51. Xu F, Yan Q, Wang H, Niu J, Li L, Zhu F, He S, Zhang S, Weng Z, Cheng T, Cai Y, He D, Chen Y, Ge S, Yeo AE, Zhang J, Ng MH, Xia N. Performance of Detecting IgM Antibodies against Enterovirus 71 for Early Diagnosis. *PLoS One.* 2010;5:e11388. PMID: 20613983

52. Cheng LF, Wang ZQ, Li C, Lin W, Yeo AE, Jin B. Complications of endoscopic gastric variceal obturation with butyl cyanoacrylate: a retrospective analysis of 753 cases. *Clinical Gastroenterology and Hepatology* 2010; 8:760-776. PMID: 20621678

53. Jin B, Sun T, Yu XH, Liu CQ, Yang YX, Lu P, Fu SF, Qiu HB, Yeo AE. Immunomodulatory Effects of dsRNA and Its Potential as Vaccine Adjuvant *Journal of Biomedicine and Biotechnology*, 2010; 2010:690438. PMID: 20671921

54. Zhang YL, Cheng T, Cai YJ, Yuan Q, Liu C, Zhang T, Xia DZ, Li RY, Yang LW, Wang YB, Yeo AE, Shih JW, Zhang J, Xia NS. RNA Interference inhibits Hepatitis B Virus of different genotypes in Vitro and in Vivo. *BMC Microbiol.* 2010; 10:214. PMID: 20696079

55. Naylor JM, Ko V, Rougellis S, Green N, Hackett D, Magrath A, Barnett A, Kim G, White M, Nathan P, Harmer A, Mackey M, Heard R, Yeo AE, Adie S, Harris IA, Mittal R, Cho A. Is discharge knee range of motion a useful and relevant clinical indicator after total knee replacement? Part 1. *J Eval Clin Pract.* 2012; 18:644–651. PMID: 21414107

56. Naylor JM, Ko V, Rougellis S, Green N, Mittal R, Heard R, Yeo AE, Barnett A, Hackett D, Saliba C, Smith N, Mackey M, Harmer A, Harris IA, Adie S, McEvoy L. Is discharge knee range of motion a useful and relevant clinical indicator after total knee replacement? Part 2 *J Eval Clin Pract.* 2012; 18:652-658. PMID: 21414108

57. Bui P, Wong V, Yeo AET, Russell H, Depczynski B. Assessing the influences on therapeutic intensification in type 2 diabetes mellitus according to career stage. *Diabetes Research and Clinical Practice* 2011; 93:385-389. PMID: 21592606

58. Chen YW, Luo WX, Song H, Yin B, Tang J, Chen YX, Ng MH, Yeo AE, Zhang J, Xia NS. Mimotope ELISA for Detection of Broad Spectrum Antibody against Avian H5N1 Influenza Virus. *PLoS ONE* 6: e24144. PMID: 21912666

59. Naylor JM, Yeo AE, Mittal R, Ko VW, Harris IA. Improvements in knee range and symptomatic and functional behavior after knee arthroplasty based on pre-operative restriction in range. *The Journal of Arthroplasty.* 2011, 27:1100-1105. PMID: 22054903

60. Liaw ST, Taggart J, Dennis S, Yeo A. Data quality and fitness for purpose of routinely collected data - a general practice case study from an electronic Practice-Based Research Network (ePBRN). *AMIA Annu Symp Proc.* 2011; 2011:785-794. PMID: 22195136

61. Yeo AET, Berney CR. Carolinas Comfort Scale for mesh repair of inguinal hernia. *ANZ*

Journal of Surgery 2012; 82:285–286. PMID: 22510195

62. Kadappu KK, Boyd A, Eshoo S, Haluska B, Yeo AE, Marwick TH, Thomas L. Changes in left atrial volume in diabetes mellitus: more than diastolic dysfunction? *Eur Heart J Cardiovasc Imaging*. 2012 13:1016-1023. PMID: 22544873

63. Zhang T, Cheng T, Wei L, Cai Y, Yeo AE, Han J, Yuan YA, Zhang J, Xia N. Efficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct. *Virology*. 2012; 9: 118. PMID: 22709537

64. Jin B, Sun T, Yu XH, Yang YX, Yeo AE. The Effects of TLR Activation on T-Cell Development and Differentiation. *Clinical and Developmental Immunology*. 2012; 2012:836485. PMID: 22737174

65. Johnson M, Schmeid V, Lupton SJ, Austin MP, Matthey SM, Kemp L, Meade T, Yeo AE. Measuring perinatal mental health risk. *Arch Womens Ment Health*. 2012; 15:375-386. PMID: 22851128

66. Liaw ST, Rahimi A, Ray P, Taggart J, Dennis S, de Lusignan S, Jalaludin B, Yeo AE, Talaei-Khoei A. Towards an ontology for data quality in integrated chronic disease management: A realist review of the literature. *International journal of medical informatics*. *Int J Med Inform*. 2013; 82:10-24. PMID: 23122633

67. George A, Shamim S, Johnson M, Dahlen H, Ajwani S, Bhole S, Yeo AE. How do dental and prenatal care practitioners perceive dental care during pregnancy? Current evidence and implications. *Birth*. 2012; 39:238-247. PMID: 23281906

68. Berney CR, Yeo AE. Mesh fixation with fibrin sealant during endoscopic totally extraperitoneal inguinal hernia approach: a review of 640 repairs. *Hernia*. 2013; 17:709-717. PMID: 23344667

69. George A, Johnson M, Blinkhorn A, Ajwani S, Bhole S, Yeo AE, Ellis S. The oral health status, practices and knowledge of pregnant women in South-western Sydney. *The Australian Dental Journal*. 2013; 58: 1-8. PMID: 23441789

70. Schmied V, Johnson M, Naidoo N, Austin MP, Matthey S, Kemp L, Mills A, Meade T, Yeo A. Maternal mental health in Australia and New Zealand: A review of longitudinal studies. *Women Birth*. 2013; 26:167-178. PMID: 23583667

71. Ko V, Naylor JM, Harris IA, Crosbie J, Yeo AE. The Six-minute walk test is an excellent predictor of functional ambulation after total knee arthroplasty. *BMC Musculoskeletal Disorders*. 2013; 14:145. PMID: 23617377

72. Windsor AA, Koh ES, Allen S, Gabriel GS, Yeo AE, Allison R, van der Linden YM, Barton MB. Poor outcomes after whole brain radiotherapy in patients with brain metastases: results from

an international multicentre cohort study. *Clinical Oncology (Royal College of Radiology)*. 2013; 25:674-680. PMID: 23906722

73. Jin B, Yeo AE. Editorial: cancer immunotherapy: does an increasing arsenal of tools point to more fruitful avenues for research? *Anticancer Agents in Medicinal Chemistry*. 2014; 14: 181-182. PMID: 24237216

74. Jin B, Cheng LF, Wu K, Yu XH, Yeo AE. Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends. *Anticancer Agents in Medicinal Chemistry*. 2014; 14: 241-255. PMID: 24237222

75. Johnson M, George A, Dahlen H, Ajwani S, Bhole S, Blinkhorn A, Ellis S, Yeo A. The midwifery initiated oral health-dental service protocol: an intervention to improve oral health outcomes for pregnant women. *BMC Oral Health*. 2015 15;15:2. PMID: 25588410

76. Sun T, Gao GZ, Li RF, Li X, Li DW, Wu SS, Yeo AE, Jin B. Bone marrow-derived mesenchymal stem cell transplantation ameliorates oxidative stress and restores intestinal mucosal permeability in chemically induced colitis in mice. *Am J Transl Res*. 2015 15;7:891-901. PMID: 26175850

77. Klevens RM, Canary L, Huang X, Denniston MM, Yeo AE, Pesano RL, Ward JW, Holmberg S. The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States. *Clin Infect Dis*. 2016; 63:1049-1055. PMID: 27506688

78. George A, Lang G, Johnson M, Ridge A, de Silva AM, Ajwani S, Bhole S, Blinkhorn A, Dahlen HG, Ellis S, Yeo A, Langdon R, Carpenter L, Heilbrunn-Lang A. The evaluation of an oral health education program for midwives in Australia. *Women Birth*. 2016; 29:208-213. PMID: 26552339

79. George A, Dahlen HG, Blinkhorn A, Ajwani S, Bhole S, Ellis S, Yeo A, Elcombe E, Sadozai A, Johnson M. Measuring oral health during pregnancy: sensitivity and specificity of a maternal oral screening (MOS) tool. *BMC Pregnancy Childbirth*. 2016; 16:347-351. PMID: 27829388

80. Lipsky PE, Yeo AE. Pharmacokinetics May Be Factor in Success of Pegloticase Therapy for Gout. *The Rheumatologist*. October 11, 2016. <https://www.the-rheumatologist.org/article/pharmacokinetics-may-factor-success-pegloticase-therapy-gout/>

81. Calabrese LH, Kavanaugh A, Yeo AE, Lipsky PE. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. *Arthritis Res Ther*. 2017;19:191. doi: 10.1186/s13075-017-1396-8. PMID: 28818095

82. George, A., Dahlen, H., Blinkhorn, A., Ajwani, S., Bhole, S., Ellis E., Yeo, A., Elcome, E., Johnson, M. (2018) Evaluation of a midwifery initiated oral health-dental service program to improve oral health and birth outcomes for pregnant women: A Multi Centre Randomised Controlled Trial. 2018;82:49-57. doi: 10.1016/j.ijnurstu.2018.03.006. PMID: 29605753

83. Mandell BF, Yeo AE, Lipsky PE. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. *Arthritis Res Ther*. 2018;20:286. doi: 10.1186/s13075-018-1782-x. PMID: 30594229

84. Lawrence Edwards N, Singh JA, Troum O, Yeo AE, Lipsky PE. Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase. *Rheumatology (Oxford)*. 2019. pii: kez017. doi: 10.1093/rheumatology/kez017. PMID: 30843588

85. Johnson RJ, Choi HK, Yeo AE, Lipsky PE. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. *Hypertension*. 2019 Jul;74(1):95-101. doi: 10.1161/HYPERTENSIONAHA.119.12727. PMID: 31079535

86. Schlesinger N, Edwards L, Khanna P, Yeo AE, Lipsky PE. Evaluation of Proposed Criteria for Remission and Evidence - Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout. *ACR Open Rheumatology* 2019; 23;1:236-243. doi: 10.1002/acr2.1025. PMID: 31777799

87. Pillinger MH, Fields T, Yeo AE, Lipsky PE. Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase. *J Rheumatol*. 2020 47:605-612. doi: 10.3899/jrheum.190161. PMID: 31203212

89. Schlesinger N, Edwards NL, Yeo AE, Lipsky PE. Development of a multivariable improvement measure for gout. *Arthritis Res Ther*. 2020; 22:164. doi: 10.1186/s13075-020-02254-4. PMID: 32600452

90. Catalina MD, Bachali P, Yeo AE, Geraci NS, Petri MA, Grammer AC, Lipsky PE. Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus. *J Clin. Investigation*. 2020; 5:e140380. doi: 10.1172/jci.insight.140380. PMID: 32759501

Chapter in a book

91. Bo J, Yeo AE Induction of innate immunity by nucleic acids: A potential adjuvant for cancer vaccines? in *Cancer Vaccines: From Research to Clinical Practice* by Adrian Bot (Editor), Mihail Obrocea (Editor), Francesco M. Marincola (Editor). ISBN-10: 1841848298; ISBN-13: 978-1841848297

Conference abstracts

1. Frances SP, Yeo AET, Brooke EW, Sweeney AW. Response of a chigger, *Eutrombicula Hirsti* to repellent and toxicant compounds in the laboratory and field. XIIIth International Congress for Tropical Medicine and Malaria Jomtien, Pattaya, Thailand , 1992 November 29th - December 4.

2. Rieckmann KH, Yeo AET, Edstein MD, Jacobus DP, Canfield CJ. Evaluation of the antimalarial activity of WR250417 (PS15) using the *in vitro* - *in vivo* model. *American Journal of Tropical Medicine and Hygiene* 1993; 49: 291-292.

3. Yeo AET, Rieckmann KH. The *in vitro* activity of ciprofloxacin and chloramphenicol against *Plasmodium falciparum*. American Journal of Tropical Medicine and Hygiene 1993; 49: 237-238.
4. Yeo AET, Rieckmann KH. The *in vitro* activity of PS-15 in *Saimiri sciureus* monkeys against *Plasmodium falciparum*. American Journal of Tropical Medicine and Hygiene 1994; 51: 254.
5. Edstein MD, Yeo AET, Kyle DE, Looareesuwan S, Canfield CJ, Hutchinson DBA, Rieckmann KH. Proguanil polymorphism does not affect the antimalarial activity of atovaquone combined with proguanil *in vitro*. American Journal of Tropical Medicine and Hygiene 1994; 51: 261-262.
6. Christopherson RI, Seymour KK, Yeo AET. Pyrimidine antagonists and antifolates as antimalarial drugs. Clinical Biochemistry 1997; 30: 8.
7. Alter HJ, Matsumoto A, Yeo AET, Shih JW. The role of TT virus in transfusion-associated hepatitis Transfusion 1998; 38 (suppl): P3.
8. Matsumoto A, Yeo AET, Shih WK, Tanaka E, Kiyosawa K, Alter HJ. Transfusion associated TT virus infection and its relationship to liver disease. 6th International Symposium on Hepatitis C and related viruses. 1999; June 6-9, poster 10.1.
9. Yeo AET, Ghany M, Melpolder JC, Shih JW, Hoofnagle J, Alter HJ. Long term follow-up of HCV-RNA in chronic carriers. 6th International Symposium on Hepatitis C and related viruses. 1999 June 6-9, poster 10.42.
10. Tan D, Matsumoto A, Yeo A, Shih JWK, Alter HJ, Yu MW. Detection of TT virus in factor VIII concentrates and other plasma derivatives. 6th International Symposium on Hepatitis C and related viruses. 1999 June 6-9, poster 10.43.
11. Alter HJ, Melpolder JC, Ghany MG, Shakil O, Conry-Cantilena C, Schechterley CA, Yeo AE, Tan D, Hoofnagle JH. A prospective study of risk factors, viral persistence and severity of liver disease. 6th International Symposium on Hepatitis C and related viruses. 1999 June 6-9, oral 10.1.
12. Kessler J, Alter HJ, Yeo A, Melpolder JC. Evaluation of ALT elevations in volunteer blood donors: etiology, persistence and morbidity. Transfusion 1999; 39(Suppl. S): 115S.
13. Yeo AET, Conry-Cantilena C, Melpolder JC, Ghany M, Kleiner D, Shih JWK, Hoofnagle JH, Alter HJ. Variations in HCV-RNA levels in chronically infected patients and their relationship to disease severity. Antiviral Chemotherapy 2000; 5: 71.
14. Umemura T, Donahue P, Scottini A, Yeo AET, Wang RY, Shih JWK, Primi D, Alter HJ. The incidence of SEN virus infection in transfusion-associated hepatitis. Antiviral Chemotherapy 2000; 5: G11.
15. Umemura T, Yeo AET, Wang RY, Shih JWK, Alter HJ. The Prevalence of SEN Virus

Infection in Transfusion-Associated Hepatitis. Poster E-28, NIH Research Festival, Bethesda, USA, 2000 October 10th-13th.

16. Umemura T, Yeo AET, Wang RY, Shih JWK, Donahue P, Primi D, Alter HJ. The Incidence of SEN Virus Infection in Transfusion-Associated Hepatitis. *Hepatology* 2000; 32: #244.

17. Umemura T, Yeo AET, Shih JWK, Matsumoto A, Orii K, Tanaka E, Kiyosawa K, Primi D, Alter HJ. The prevalence of SEN virus infection in Japanese patients with viral hepatitis and liver disease. *Hepatology* 2000; 32: #885.

18. AET Yeo, Y Tanaka, R Pfeiffer, T Umemura, KH Seal, JWK Shih, HJ Alter, BR Edlin, TR O'Brien. SEN viruses are common in injection drug users in San Francisco. 2001 American Journal of Epidemiology 2001; 153 (suppl): Abstract Number: 1020.

19. Umemura T, Alter HJ, Tanaka E, Yeo AE, Shih JW, Orii J, Matsumoto A, Yoshizawa K, Kiyosawa K. SEN virus infection in high- and non-endemic areas for hepatitis C in Japan. *Hepatology* 2001; 34: #1262.

20. Umemura T, Alter HJ, Tanaka E, Orii K, Yeo AET, Shih JWK, Matsumoto A, Yoshizawa K, Kiyosawa K. SEN virus: response to interferon-alfa and influence on the severity and treatment response of coexistent hepatitis C. 9th International Symposium on Hepatitis C and Related Viruses La Jolla, CA, USA, July 7-11, 2002.

21. Umemura T, Tanaka E, Lee WM, Ostapowicz G, Heringlake S, Manns MP, Tassopoulos NC, Hatzakis A, Brown KE, Young NS, Wang W, Yeo A, Shih J, Orii K, Kiyosawa K. The role of SENV virus infection in various liver diseases from different geographical areas. *Hepatology* 2002; 36: #1934.

22. Tanaka Y, Alter HJ, Hanada K, Yeo AE, Shih JW, Mizokami M, Gojobori T. A comparison of the evolutionary clock of Hepatitis C virus infection in the United and Japan predicts that hepatocellular carcinoma incidence in the US will increase over the next two decades. *Hepatology* 2002; 36: #727.

23. Yeo AET, Sklaney M, Cynamon MH, Jacobus DP. WR99210 alone and in combination with dapsone or sulfamethoxazole against *Mycobacterium tuberculosis* U-081. General meeting of the American Society of Microbiology, Washington DC May 18-22, 2003.

24. Yeo AET, Cynamon MH, Jacobus DP. The drug combination of WR99210 and dapsone against *M. avium*. U-082. General meeting of the American Society of Microbiology, Washington DC May 18-22, 2003

25. Hurlburt KJ, Mayo M, Homan C, Yeo A, Gove J, Williams J, Livingston D, McMahon B. TPMT Activity Related to Azathioprine Dosing and Treatment of Autoimmune Hepatitis. *Hepatology* 2005; 42; Suppl.1:291A.

26. Yeo A, Kaidarova Z, Gobble J, Smith J, Newman B, Garratty G, Fridey J, Sacher, and

Murphy E. Long-term abnormalities of complete blood counts in human T-lymphotropic virus type I and type II (HTLV-I and -II) infection. 13th International Conference on Human Retrovirology. HTLV and related viruses. Tokyo, Japan 2007. AIDS Research and Human Retroviruses, 2007; 23; P-220.

27. Kaidarova Z, Yeo AE, Kamel HT, Busch MP, Murphy EL. HIV Seroprevalence among US Blood donors 2001-2006: Evidence for a 'Hidden Epidemic'? Transfusion 2007; 47; Supplement: Abstract SP136.

28. Gastanaga V, Wentworth C, Yeo A, Hughes G, Ji M, Zhao S. Incidence rates of thromboembolic events in solid tumor cancer patients in the THIN database. Pharmacoepidemiology and Drug Safety 2009; 18; S190.

29. Gastanaga V, Wentworth C, Yeo A, Hughes G, Haddock W, Zhao S. Incidence rates of ards in solid tumor cancer patients in the THIN Database, Pharmacoepidemiology and Drug Safety 2009; 18; S259.

30. Gastanaga V, Wentworth C, Yeo A, Hughes G, Cha S, Zhao S. Renal Impairment among Adult ITP Patients: Use of GPRD for Proactive Safety Surveillance. Pharmacoepidemiology and Drug Safety 2009; 18; S582.

31. Kim, LHC, Heath T, Yeo A.E.T, Deva AK. Comparison of intramedullary fixation versus plate and screw fixation techniques for metacarpal fractures. Presented at the 2011 Australian Hand Surgery Society Annual Scientific Meeting. Quay West Bunker Bay, Western Australia. 16 –20, March 2011.

32. Bhole S, George A, Ajwani S, Johnson M, Duff M, Dahlen H, Blinkhorn A, Ellis S, Yeo A. Dental health education for prenatal care providers: An Australian Initiative. FDI Annual World Dental Congress conference, Mexico City, 14-17th Sept 2011.

33. Ko V, Naylor JM, Harris IA, Crosbie J, Yeo A. "Is a thirty-minute walk test a useful measure of functional ambulation after knee replacement?" APA Physiotherapy Conference 2011, Brisbane, Australia.

34. Duggan K, Vinod SK, Yeo A. Treatment patterns for lung cancer in South Western Sydney, Australia: Do patients get treated according to guidelines? World Conference on Lung Cancer, Amsterdam 2011. J Thorac Oncol 2011;6 (S2):S1575 (P 4.1014).

35. Jameson, M., M. Bailey, K. Foo, L. Holloway, A. E. T. Yeo and P. Metcalfe. (2011). Methodology for assessment of impact of contouring variation on clinical trial design. EPSM-ABEC. Darwin, NT, Australia.

36. Liaw ST, Taggart J, Dennis S, Yeo AET. Data quality and fitness for purpose of routinely collected data – a case study from an electronic Practice-Based Research Network (ePBRN). Proceedings of the AMIA Annual Symposium 2011, Washington DC, USA.

37. Ip E, Yeo AE, Rubello I, Berney C. Totally extraperitoneal hernia repair with mesh fixation by fibrin glue: safety and outcomes. 2011 Annual scientific meeting of the General Surgeons Australia. Darwin, Australia.
38. Lawler J, Glass A, Chatterjee U, Wiseman E, Davison S, Manoharan S, Smith L, Yeo A, Ayres A, Locarnini S, Nucleot(s)ide analogues to prevent perinatal transmission of HBV. Lamivudine is effective but Tenofovir may be better. American Association for the study of liver diseases. San Francisco 2011. November 4-8th.
39. Johnson, M., Suominen, H., Hanlen, L., Dawson, L., Basilakis, J., Yeo, A. Overs. B. Using speech-to-text (STT) technology in nursing health communication. Presented on 7th December 2011 at the Researching Communication at the University of Western Sydney: Brain, Behaviour and Computation, at University of Western Sydney, Bankstown, Sydney. Australia.
40. Berney CR, Yeo, A. Technique of Mesh Fixation with Fibrin Sealant: Safety and Outcome of 640 Endoscopic Extraperitoneal Inguinal Hernia Repairs. 2012 World Hernia Congress March 28-31, 2012 New York Marriott Marquis New York, NY. Hernia 2012; 16 (Suppl 1): S168.
41. George A, Bhole S, Johnson M, Dahlen H, Ajwani S, Blinkhorn A, Yeo A, Ellis S. Perceptions of Dental and Health Professionals Towards Perinatal Oral Health. IADR conference, Iguca Falls, Brazil, June 20-23, 2012.
42. Schmied, V., Johnson, M., Matthey, S., Austin, M-P., Kemp, L., Covic, T., Langdon, R., & Yeo, A. Perinatal mental health: psychosocial risk, service utilisation and mental health outcomes for women 12 months birth. Marce International society biennial conference 2012; October 3rd to 5th.
43. Bahrt KM, Yeo AE, Howson TL, Ottery FD. Post-marketing surveillance data reveals patterns of use for Pegloticase in Refractory Chronic Gout. Presented at the Annual meeting of the American College of Rheumatology, Washington DC 2012, abstract 169.
44. Malamet RL, Howson TL, Yeo AE, Bahrt KM, Wolfson M. Relative risk of Infusion reactions with KRYSTEXXA® (Pegloticase) from Post-Approval Safety data: Results from September 2010 to June 2012. Presented at the Annual meeting of the American College of Rheumatology, Washington DC 2012, abstract #170.
45. Bahrt K, Yeo A, Howson T, Ottery, F. Uric acid levels as a biomarker of efficacy and safety in patients treated with pegloticase: lessons learned from us clinical experience. EULAR, 2013, Madrid, Spain
46. Malamet R, Howson T, Yeo A, Bahrt K. Real world risk of infusion reactions with pegloticase treatment: findings from post-approval us safety data. EULAR, 2013, Madrid, Spain.
47. Klevens M, Huang X, Thakare D, Yeo A, Odeh M, John W. Preliminary Assessment of Hepatitis C Antibody Testing in the United States Before and After Publication of CDC

Screening Recommendations. Abstract 1456. American Association for the Study of Liver Diseases 2014, Boston, USA.

48. M Klevens, X Huang, AE Yeo, J Ward, et al. The Burden of Liver Disease Among Persons With Hepatitis C in the United States. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 145.

49. Mandell BF, Weisman M, Yeo A, Lipsky PE. Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response. American College of Rheumatology Annual Meeting, Abstract 212. Washington DC November 2016.

50. Mandell B, Yeo A, Lipsky P. Rapid tophus resolution in chronic refractory gout patients treated with Pegloticase. Annual European Congress of Rheumatology Madrid, Spain, 14-17 June 2017.

51. Calabrese L, Kavanaugh A, Yeo A, Lipsky P. Lack of predictive value of the NIAID/FAAN criteria to identify subjects with evidence of immune activation after receiving Pegloticase for chronic refractory gout. Annual European Congress of Rheumatology Madrid, Spain, 14-17 June 2017.

52. Edwards NL, Singh J, Troum O, Yeo A, Lipsky P. Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi: response to Pegloticase. Annual European Congress of Rheumatology Madrid, Spain, 14-17 June 2017.

53. Schlesinger N, Khanna P, Yeo A, Lipsky P. Evidence based development of criteria for complete response in patients with chronic refractory gout. Annual European Congress of Rheumatology Madrid, Spain, 14-17 June 2017.

54. Mandell BF, Baraf HS, Yeo A and Lipsky PE. Rapid Tophus Resolution in Chronic Refractory Gout Patients Treated with Pegloticase. Abstract 2067; 2017 ACR/ARHP Annual Meeting; San Diego, California.

55. Hyon KC, Johnson R, Yeo A and Lipsky PE. Treatment with Pegloticase Significantly Decreases Mean Arterial Blood Pressure in Patients with Chronic Gout. Abstract 2067; 2017 ACR/ARHP Annual Meeting, San Diego, California.

56. Lipsky PE, Johnson RJ, Choi H, Yeo, A. Pegloticase, a Mammalian Uricase, Significantly Decreases Mean Arterial Blood Pressure in Patients with Chronic Gout. Abstract FR-PO582. American Society of Nephrology Annual Meeting, New Orleans, Louisiana, 2017.

57. Calabrese L, Fields T, Yeo A, Lipsky P. The frequency of flares in subjects with chronic refractory gout treated with pegloticase is related to variation in the level of plasma urate. Abstract OP0184. Annals of the Rheumatic Diseases. June 2018, Volume 77 supplement 2. DOI: 10.1136/annrheumdis-2018-eular.5961.

58. Choi H, Johnson R, Yeo A, Lipsky P. Pegloticase treatment significantly decreases mean arterial blood pressure in patients with chronic gout Abstract FRI0237. *Annals of the Rheumatic Diseases*. June 2018, Volume 77 supplement 2. DOI: 10.1136/annrheumdis-2018-eular.5616.
59. Mandell B, Yeo A, Lipsky P. Factors influencing tophus resolution in patients with persistent urate lowering responses to pegloticase. Abstract SAT0356. *Annals of the Rheumatic Diseases*. June 2018, Volume 77 supplement 2. DOI: 10.1136/annrheumdis-2018-eular.5799.
60. Edwards NL, Singh J, Troum O, Yeo A, Lipsky P. Association of renal dysfunction and development of tophi in subjects with chronic refractory gout and response to treatment with pegloticase Abstract SAT0370. *Annals of the Rheumatic Diseases*. June 2018, Volume 77 supplement 2. DOI: 10.1136/annrheumdis-2018-eular.5666.
61. Pillinger MH, Fields T, Yeo A, Lipsky P. A transient decrease in serum urate changes the clinical trajectory of subjects with advanced gout. *Annals of the Rheumatic Diseases*, June 2019, Volume 78, supplement 2, page A1306.
62. Schlesinger N, Lawrence Edwards N, Yeo A, Lipsky P. Development of a multivariable improvement measure for gout. *Annals of the Rheumatic Diseases*, June 2019, volume 78, supplement 2, page A97.
63. Schlesinger N, Lawrence Edwards N, Yeo A, Lipsky P. Development of a multivariable improvement measure for gout. *American College of Rheumatology 2019*, abstract number 341, Annual Scientific meeting of the American College of Rheumatology, Atlanta, Georgia 2019.
64. Schlesinger N, Yeo A, Lipsky P. Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase, 2019, abstract number 1231, Annual Scientific meeting of the American College of Rheumatology, Atlanta, Georgia 2019.
65. Saxena A, Karp D, Rovin B, Boesen M, Kubassova O, Dykas C, Yeo A, Lipsky P. Development of a Multi-Modality Imaging Approach to Evaluate Lupus Nephritis, 2019, abstract number 1919, Annual Scientific meeting of the American College of Rheumatology, Atlanta, Georgia 2019.
66. Catalina M, Bachali P, Yeo A, Geraci N, Petri M, Grammer A, Lipsky P. Ancestry Influences the Gene Expression Profile in Systemic Lupus Erythematosus and Contributes to Transcriptomic Heterogeneity in Lupus Patients, 2019, abstract number 2019, Annual Scientific meeting of the American College of Rheumatology, Atlanta, Georgia 2019.
67. N. Schlesinger N, Yeo A, Lipsky P. Treatment with pegloticase improves Hepatic fibrosis estimated by Fibrosis-4 index in subjects with Chronic refractory gout. *European League Against Rheumatism conference online*. Abstract 433.

68. Rainey H, Baraf HSB, Yeo A, Lipsky P. Companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout. European League Against Rheumatism conference online. Abstract 410.

Last modified 1 October, 2020